Michael Baran, Executive Director at WRDM and partner at Pfizer Ventures, delves into the revolutionary potential of decentralized science (DeSci). He explores how DeSci is redefining traditional biotech paradigms and enhancing investment models through decentralized autonomous organizations (DAOs). Michael discusses the risks in early-stage science investments, challenges in biopharma, and common misconceptions about the sector. He emphasizes the importance of maintaining scientific quality while navigating the complexities of innovation and funding in the evolving landscape.